Sonova Holding AG stock (CH0012549785): Citi cuts price target to CHF169

Citi analyst lowered the price target for Sonova Holding AG to CHF169 amid hearing aid sector challenges, as reported on May 13, 2026. The stock traded at 178.20 CHF on May 12, 2026 on SIX Swiss Exchange.

Sonova Holding AG (CH0012549785), a leading provider of hearing care solutions, saw Citi analyst Veronika Dubajova lower the price target to CHF169 from a prior level, signaling caution amid market pressures in the medtech sector, Ad-hoc-news.de as of May 13, 2026. The stock traded at 178.20 CHF on May 12, 2026 on SIX Swiss Exchange, up 1.25%, Marketscreener as of 12.05.2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Sonova Holding AG
• Sector/industry: Medtech / Hearing care
• Headquarters/country: Switzerland
• Core markets: Europe, North America
• Key revenue drivers: Hearing instruments, cochlear implants
• Home exchange/listing venue: SIX Swiss Exchange (SOON)
• Trading currency: CHF

Sonova Holding AG: core business model

Sonova Holding AG develops, manufactures and distributes hearing instruments and cochlear implants worldwide. The company operates through brands like Phonak, Unitron and Advanced Bionics, serving audiologists, clinics and retail channels, Ad-hoc-news.de as of May 2026. Sonova is a global market leader in innovative hearing solutions with a broad product portfolio including traditional hearing aids and wireless communication systems.

Main revenue and product drivers for Sonova Holding AG

Hearing instruments represent the primary revenue driver for Sonova Holding AG, complemented by cochlear implants and accessories. North America and Europe form core markets, with strong exposure to the aging population trend driving demand for audiology solutions. The company's focus on premium hearing care products supports its position in the medtech space.

Why Sonova Holding AG matters for US investors

Sonova Holding AG trades OTC in the US as SONVY, offering US investors exposure to a leading European medtech firm with significant North American revenue contribution. The company's products address the growing US hearing care market, influenced by demographic shifts and healthcare spending.

Conclusion

Sonova Holding AG maintains its leadership in hearing care solutions amid analyst adjustments such as Citi's recent price target reduction to CHF169. The stock's performance reflects sector dynamics, with trading at 178.20 CHF on May 12, 2026. Investors monitor ongoing medtech developments and North American market exposure for future insights.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.